Serum concentration/dose ratio of levetiracetam before, during and after pregnancy

被引：63

作者：

Westin, Andreas Austgulen ^{[1
]}

Reimers, Arne ^{[1
,4
]}

Helde, Grethe ^{[2
]}

Nakken, Karl Otto ^{[3
]}

Brodtkorb, Eylert ^{[2
,4
]}

机构：

[1] St Olavs Hosp, Dept Clin Pharmacol, N-7006 Trondheim, Norway

[2] Norwegian Univ Sci & Technol, Dept Neurosci, Trondheim, Norway

[3] Natl Ctr Epilepsy, Sandviken, Sweden

[4] St Olavs Hosp, Dept Neurol & Clin Neurophysiol, Trondheim, Norway

来源：

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2008年 / 17卷 / 02期

关键词：

epilepsy; levetiracetam; pregnancy; pharmacokinetics; clearance; elimination;

D O I：

10.1016/j.seizure.2007.11.027

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Purpose: To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy. Methods: Altogether 21 consecutive pregnancies in 20 women with epilepsy receiving LEV during gestation were studied retrospectively. The main target variable was the C/D-ratio before and during pregnancy, and in the post partum period. Secondary target variables were changes in LEV dose, concomitant use of other antiepileptic drugs and seizure frequency. Student's paired t-test and two-sample t-test for independent samples were used to test for statistically significant changes in C/D-ratio means. Results: Mean C/D-ratio in the third trimester was 50% of the mean C/D-ratio at baseline (p < 0.001, n = 11). Baseline Levels were reached within the first weeks after pregnancy. The interindividual variability was pronounced. Conclusions: Serum concentrations of LEV declined significantly in the third trimester of pregnancy and increased rapidly after delivery. (C) 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

引用

页码：192 / 198

页数：7

共 14 条

[1] Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach [J].

Anderson, GD .

CLINICAL PHARMACOKINETICS, 2005, 44 (10) :989-1008

[2] Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy [J].

Christensen, Jakob ;

Sabers, Anne ;

Sidenius, Per .

NEUROLOGY, 2006, 67 (08) :1497-1499

[3] Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug [J].

De Smedt, Tim ;

Raedt, Robrecht ;

Vonck, Kristl ;

Boon, Paul .

CNS DRUG REVIEWS, 2007, 13 (01) :57-78

[4] Effect of age and comedication on levetiracetam pharmacokinetics and tolerability [J].

Hirsch, Lawrence J. ;

Arif, Hiba ;

Buchsbaum, Richard ;

Weintraub, David ;

Lee, Jeansun ;

Chang, Jennifer T. ;

Resor, Stanley R., Jr. ;

Bazil, Carl W. .

EPILEPSIA, 2007, 48 (07) :1351-1359

[5] Levetiracetam concentrations in serum and in breast milk at birth and during lactation [J].

Johannessen, SI ;

Helde, G ;

Brodtkorb, E .

EPILEPSIA, 2005, 46 (05) :775-777

[6] Serum concentrations of levetiracetam in epileptic patients:: The influence of dose and co-medication [J].

May, TW ;

Rambeck, B ;

Jürgens, U .

THERAPEUTIC DRUG MONITORING, 2003, 25 (06) :690-699

[7] Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium [J].

Mazzucchelli, I ;

Onat, FY ;

Ozkara, C ;

Atakli, D ;

Specchio, LM ;

Neve, AL ;

Gatti, G ;

Perucca, E .

EPILEPSIA, 2006, 47 (03) :504-509

[8] Clinical pharmacokinetics of levetiracetam [J].

Patsalos, PN .

CLINICAL PHARMACOKINETICS, 2004, 43 (11) :707-724

[9]

Pennell PB, 2005, EPILEPSIA, V46, P89

[10] Antiepileptic drug pharmacokinetics during pregnancy and lactation [J].

Pennell, PB .

NEUROLOGY, 2003, 61 (06) :S35-S42

← 1 2 →